[1] Jr Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group[J]. N Engl J Med,1996, 334(26): 1697-1702. [2] Jr Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial[J]. Crit Care Med,1994, 22(1): 12-21. [3] Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment[J]. Crit Care Med,1997, 25(7): 1095-1100. [4] Fuentes JM, Talamini MA, Fulton WB, et al. General anesthesia delays the inflammatory response and increases survival for mice with endotoxic shock[J]. Clin Vaccine Immunol,2006, 13(2): 281-288. [5] Plachinta RV, Hayes JK, Cerilli LA, et al. Isoflurane pretreatment inhibits lipopolysaccharide-induced inflammation in rats[J]. Anesthesiology,2003, 98(1): 89-95. [6] Litman RS, Soin K, Salam A. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications[J]. Anesth Analg,2010, 110(3): 739-746. [7] Gallos G, Jones DR, Nasr SH, et al. Local anesthetics reduce mortality and protect against renal and hepatic dysfunction in murine septic peritonitis[J]. Anesthesiology,2004, 101(4): 902-911. [8] de Klaver MJ, Manning L, Palmer LA, et al. Isoflurane pretreatment inhibits cytokine-induced cell death in cultured rat smooth muscle cells and human endothelial cells[J]. Anesthesiology,2002, 97(1): 24-32. [9] Pan Q, Liu Y, Zheng J, et al. Protective effect of chloral hydrate against Lipopolysaccharide/d-galactosamine-induced acute lethal liver injury and zymosan-induced peritonitis in mice[J]. Int Immunopharmacol,2010, 10(8):967-977. [10] Tschaikowsky K, Ritter J, Schroppel K, et al. Volatile anesthetics differentially affect immunostimulated expression of inducible nitric oxide synthase: role of intracellular calcium[J]. Anesthesiology,2000, 92(4): 1093-1102. [11] Shiga M, Nishina K, Mikawa K, et al. The effects of lidocaine on nitric oxide production from an activated murine macrophage cell line[J]. Anesth Analg,2001,92(1): 128-133. [12] Berg JO, Mossner BK, Skov MN, et al. Antibacterial properties of EMLA and lidocaine in wound tissue biopsies for culturing[J]. Wound Repair Regen,2006,14(5): 581-585. [13] Goodman EJ, Jacobs MR, Bajaksouzian S, et al. Clinically significant concentrations of local anesthetics inhibit Staphylococcus aureus in vitro[J]. Int J Obstet Anesth,2002,11(2): 95-99. [14] Mitsuhata H, Shimizu R, Yokoyama MM. Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells[J]. Int J Immunopharmacol,1995, 17(6): 529-534. [15] Humar M, Pischke SE, Loop T, et al. Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells[J]. Mol Pharmacol,2004,65(2): 350-361. [16] Galley HF, Dimatteo MA, Webster NR. Immunomodulation by anaesthetic, sedative and analgesic agents: does it matter[J] ? Intensive Care Med,2000,26(3): 267-274. [17] Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients[J]. Curr Opin Support Palliat Care, 2009,3(3): 213-218. [18] Yuki K, Astrof NS, Bracken C, et al. The volatile anesthetic isoflurane perturbs conformational activation of integrin LFA-1 by binding to the allosteric regulatory cavity[J]. FASEB J,2008,22(12): 4109-4116. [19] Dzoljic M, Bene L, Krasznai Z, et al. Ethanol and halothane differently modulate HLA class I and class II oligomerization. A new look at the mode of action of anesthetic agents through fluorescence spectroscopy[J]. J Photochem Photobiol B,2000,56(1): 48-52. [20] Cavo M, di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma[J]. J Clin Oncol,2009,27(30):5001-5007. |